The Cerebrovascular Disease Center of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine was officially established in May 2021. The establishment of the Cerebrovascular Disease Center is not only an important measure for hospitals to deepen medical system reform and implement the 14th Five Year Plan for medical technology development, but also a milestone for the people's demand for physical health and the improvement of discipline construction. The Cerebrovascular Disease Center is jointly established by experts and doctors specializing in cerebrovascular disease from the Department of Neurology and Neurosurgery. It adheres to the integrated scientific diagnosis and treatment model of stroke with patients as the center and diseases as the guide, breaks traditional disciplinary boundaries, optimizes disciplinary resource allocation, and is a clinical diagnosis and research platform for cerebrovascular diseases that integrates "medicine, education, research, prevention, and management".

At present, our cerebrovascular disease center has two wards and one neuro intensive care unit (NICU) ward in the southern campus, with 48 open beds. It has an independent 24-hour emergency department, a 5-and-a-half-day weekly general outpatient clinic, as well as specialized outpatient clinics for stroke prevention and screening, cerebrovascular intervention, headache, and post-stroke cognitive impairment. There are currently 17 physicians, including 3 chief physicians, 3 deputy chief physicians, 7 attending physicians, and 4 resident physicians, all of whom hold graduate degrees or above. The center is equipped with complete equipment, including video electroencephalography, dynamic electroencephalography, electromyography, dynamic electrocardiogram, dynamic blood pressure, color Doppler ultrasound diagnosis, transcranial magnetic stimulation, pneumatic therapy, centrifuge, ultra-low temperature refrigerator, and other equipment.

Under the leadership of the discipline leader, Director Wan Jieqing, the center is guided by the demand for prevention and treatment of cerebrovascular diseases, adopts the internationally advanced comprehensive stroke center diagnosis and treatment model, and establishes a fast treatment channel for acute cerebrovascular diseases. In terms of stent treatment for intracranial and extracranial artery stenosis, interventional treatment for complex intracranial aneurysms, minimally invasive surgical treatment for cerebral hemorrhage, and comprehensive treatment for cerebrovascular diseases, the center has reached a high international level. Its "integrated, standardized, and procedural" stroke diagnosis and treatment model is bringing good news to patients. In the past three years since its establishment, the center has continuously improved its team building and encouraged every physician to actively innovate and forge ahead. Based on the deep integration of neurologists and neurosurgeons, it has established three teams for cerebrovascular disease intervention and surgery, neurological critical care, and comprehensive treatment. And collaborate with the neurosurgery cerebrovascular disease team of the East Campus to carry out various difficult surgeries in unison, gradually forming a specialized cerebrovascular disease treatment system with Renji characteristics. As of the end of December 2023, more than 4000 patients were admitted to the East and South Campus annually, with nearly 60000 cases in outpatient and emergency departments. More than 250 cases of acute stroke were treated with emergency thrombectomy, and over 200 cases were treated with emergency arterial hemorrhage intervention. Over 2000 surgical procedures were performed for intracranial and extracranial artery stenosis or occlusion, cerebral hemorrhage, minimally invasive intervention or clipping of cerebral aneurysms, and cerebrovascular bypass grafting, significantly improving the survival rate and quality of life of patients with cerebrovascular diseases.

In terms of scientific research, under the leadership of Director Wan Jieqing, the center actively participated in multiple clinical and basic research projects, applied for multiple national natural and national level projects, published multiple papers in international first-class journals, and won the third prize of Shanghai Medical Science and Technology Award (first completion) in 2022. In terms of new technologies, the center has carried out monitoring of vascular ultrasound such as TCD before and during intervention surgery to reduce perioperative complications and actively apply for the promotion and application of new technologies. In terms of academic exchange, since its establishment, the Center for Cerebrovascular Diseases has held the "PuJiang Cerebrovascular Disease Forum" and other academic exchange activities every year, providing a platform for scientists and researchers in the field of cerebrovascular diseases to explore the current basic and clinical research frontiers of cerebrovascular diseases and related diseases, accelerate innovation and transformation in the prevention and treatment of cerebrovascular diseases, and promote the vigorous development of the discipline. In terms of certification training, the center has obtained certifications from national pharmacological bases and medical device bases, and the center's doctors have obtained GCP certificates. The center also obtained the first batch of national neurointerventional training and training base certification in 2021. It has trained dozens of advanced physicians from multiple hospitals in China, promoting treatment methods for cerebrovascular diseases, and its influence is constantly radiating nationwide. In terms of clinical cooperation, the center conducts cross hospital clinical cooperation and collaborates with Eye&ENT Hospital of Fudan University to perform carotid artery embolization on patients with nasopharyngeal carcinoma invading the internal carotid artery through various surgical methods, thereby reducing the possibility of intracranial hemorrhage in patients. The overall 3-year survival rate and tumor progression free survival rate of patients have significantly increased from 27.7% and 18.9% to 69.1% and 33.9%, respectively. In terms of grassroots education, the center has also established medical alliances with multiple rehabilitation hospitals, regularly conducting community education, opening specialized disease clinics, and teaching rounds. The center has also made good progress in various science popularization work, regularly updated the official account of "How Much Do You Know About Stroke", and won many awards for community science popularization with the community hospital.